Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 10, 2016. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director, Manager, or Representative (PDMR), rather than a periodic financial report.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific individual transaction:
- Instrument: GlaxoSmithKline plc American Depositary Shares (ADSs)
- Transaction Price: $42.96 per ADS
- Transaction Volume: 2 ADSs
Material Changes
No material changes to the company's financial position or operations are reported. The filing details a single increase of 2 ADSs held by Dr. K. Slaoui (PCA of Dr. M. M. Slaoui, Chairman, Global Vaccines). This increase resulted from the notional allocation of ADSs on October 7, 2016, due to the revaluation of the cash element within the GSK 401(K) plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is strictly a regulatory disclosure of a specific securities transaction.
Investor Verification Points
- Verify the identity of the PCA (Dr. K. Slaoui) and their relationship to the PDMR (Dr. M. M. Slaoui).
- Confirm the transaction date (October 7, 2016) and the price per ADS ($42.96) against market data for that period.
- Note that this filing does not reflect broader company performance; refer to Form 20-F for comprehensive financial results.